Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
Demo Company
GLOBETECH PUBLISHING LLC

HIV-Fighting Vectored Immunoprophylaxis Antibody Delivery Technique shows Potential

By BiotechDaily International staff writers
Posted on 27 Feb 2014
Image: The crystal structure of the small virus used to deliver antibodies as vectored immunoprophylaxis (VIP) against HIV (Photo courtesy of Alejandro Balazs, California Institute of Technology).
Image: The crystal structure of the small virus used to deliver antibodies as vectored immunoprophylaxis (VIP) against HIV (Photo courtesy of Alejandro Balazs, California Institute of Technology).
In 2011, US biologists demonstrated a very effective way to deliver HIV-fighting antibodies to laboratory mice: a treatment that protected the mice from infection by a laboratory strain of HIV delivered intravenously. The same researchers have now shown that the procedure is just as effective against a strain of HIV found in the real world, even when transmitted across mucosal surfaces.

The findings, which were published in the February 9, 2014, online publication of the journal Nature Medicine, suggest that the delivery technique might be effective in preventing vaginal transmission of HIV between humans. “The method that we developed has now been validated in the most natural possible setting in a mouse,” stated study leader Nobel Laureate Dr. David Baltimore, president emeritus and a professor of biology at California Institute of Technology (Caltech; Pasadena, USA). “This procedure is extremely effective against a naturally transmitted strain and by an intravaginal infection route, which is a model of how HIV is transmitted in most of the infections that occur in the world.”

The new Caltech delivery technology, called vectored immunoprophylaxis (VIP), is not precisely a vaccine. Vaccines introduce substances such as antigens into the body to try to get the immune system to initiate an appropriate attack, in order to generate antibodies that can stop an infection or T cells that can attack infected cells. In the instance of VIP, a small, harmless virus is injected and delivers genes to the muscle tissue, instructing it to generate specific antibodies.

The researchers emphasized that the research was conducted in lab mice and that human trials are not right around the corner. The team is now working with the vaccine research center at the national institutes of health to begin clinical evaluation.

Related Links:

California Institute of Technology



Channels

Lab Technologies

view channel
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).

High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification

A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.